[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immunome Inc (IMNM)

Immunome Inc (IMNM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,472,248
  • Shares Outstanding, K 113,250
  • Annual Sales, $ 6,940 K
  • Annual Income, $ -212,390 K
  • EBIT $ -229 M
  • EBITDA $ -229 M
  • 60-Month Beta 2.11
  • Price/Sales 367.76
  • Price/Cash Flow N/A
  • Price/Book 4.34

Options Overview Details

View History
  • Implied Volatility 98.23% (+11.43%)
  • Historical Volatility 53.33%
  • IV Percentile 37%
  • IV Rank 14.74%
  • IV High 298.95% on 09/19/25
  • IV Low 63.52% on 05/22/26
  • Expected Move (DTE 19) 2.81 (12.85%)
  • Put/Call Vol Ratio 5.31
  • Today's Volume 164
  • Volume Avg (30-Day) 177
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 6,599
  • Open Int (30-Day) 6,046
  • Expected Range 19.03 to 24.64

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.59
  • Number of Estimates 7
  • High Estimate $-0.48
  • Low Estimate $-0.70
  • Prior Year $-0.50
  • Growth Rate Est. (year over year) -18.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.45 +12.24%
on 05/19/26
24.01 -9.08%
on 05/05/26
-1.12 (-4.88%)
since 04/29/26
3-Month
19.16 +13.94%
on 03/30/26
24.90 -12.33%
on 04/20/26
-0.03 (-0.14%)
since 02/27/26
52-Week
7.96 +174.25%
on 07/15/25
27.65 -21.05%
on 02/04/26
+13.20 (+152.95%)
since 05/28/25

Most Recent Stories

More News
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting

Varegacestat treatment resulted in statistically significant improvements in primary and all key secondary efficacy endpoints Varegacestat demonstrated statistically significant improvement...

IMNM : 21.83 (-3.15%)
Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome’s...

IMNM : 21.83 (-3.15%)
Immunome Reports First Quarter 2026 Financial Results and Provides Business Update

New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) in April 2026 seeking approval of varegacestat for the treatment of adults with desmoid tumors Detailed...

IMNM : 21.83 (-3.15%)
Can Immunome's Varegacestat Data Justify What Investors Are Now Willing to Overlook?

Barchart Research What to Expect from IMNM Earnings IMNM Generated May 8, 2026 Current Price $22.44 EPS Estimate $$-0.60 Consensus Rating Strong Buy Average Move 3.95% Can Immunome's Varegacestat Data...

IMNM : 21.83 (-3.15%)
Can Immunome's Varegacestat Data Justify What Investors Are Now Willing to Overlook?

Barchart Research What to Expect from IMNM Earnings IMNM Generated May 8, 2026 Current Price $22.44 EPS Estimate $$-0.60 Consensus Rating Strong Buy Average Move 3.95% Can Immunome's Varegacestat Data...

IMNM : 21.83 (-3.15%)
Can Immunome's Varegacestat Data Justify What Investors Are Now Willing to Overlook?

Barchart Research What to Expect from IMNM Earnings IMNM Generated May 8, 2026 Current Price $22.44 EPS Estimate $$-0.60 Consensus Rating Strong Buy Average Move 3.95% Can Immunome's Varegacestat Data...

IMNM : 21.83 (-3.15%)
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on May 1, 2026, the Compensation...

IMNM : 21.83 (-3.15%)
Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors

New Drug Application (NDA) supported by positive Phase 3 RINGSIDE results, including significant improvement in progression-free survival vs. placebo (hazard ratio = 0.16, p

IMNM : 21.83 (-3.15%)
Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting

Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that data from RINGSIDE, its...

IMNM : 21.83 (-3.15%)
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on April 1, 2026, the Compensation...

IMNM : 21.83 (-3.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Average short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Immunome, Inc. is a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. Immunome, Inc. is based in Exton, United States.

See More

Key Turning Points

3rd Resistance Point 23.55
2nd Resistance Point 23.19
1st Resistance Point 22.51
Last Price 21.83
1st Support Level 21.47
2nd Support Level 21.11
3rd Support Level 20.43

See More

52-Week High 27.65
Last Price 21.83
Fibonacci 61.8% 20.13
Fibonacci 50% 17.81
Fibonacci 38.2% 15.48
52-Week Low 7.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.